Neoadjuvant carboplatin in triple-negative breast cancer: results from NACATRINE, a randomized phase II clinical trial.
Cristiano de Pádua SouzaAna Suellen Barroso CarneiroAna Cecília de Oliveira LessaDomício Carvalho LacerdaCarlos Eduardo PaivaMarina Moreira Costa ZorzettoAna Julia Aguiar de FreitasIara Viana Vidigal SantanaMarco Antonio de OliveiraEdenir Inêz PalmeroMárcia Maria Chiquitelli MarquesTomás ReinertPublished in: Breast cancer research and treatment (2023)
The addition of carboplatin to standard NACT in stages II and III TNBC was associated with a non-statistically significant numerical increase in the pCR rate. Follow-up for survival outcomes and translational research initiatives are ongoing.